Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP5354 Dose-finding for Lymph Node Visualization in Breast Cancer and Melanoma
NCT05457842Phase 2Terminated
- Sponsor
- Astellas Pharma
- Start
- Aug 2022
- Primary completion
- Sep 2022
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pudexacianinium chloride in breast cancer and melanoma, sponsored by Astellas Pharma. Primary endpoint: Optimal Dose of ASP5354 for Lymph Node (LN) Visualization at Day 1. Started Aug 2022; status: terminated.
02
Drugs
pudexacianinium chloride
03
Conditions
breast cancermelanoma
Beyond the preview
Go deeper on NCT05457842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05457842.